{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T18:22:44Z","timestamp":1766514164597,"version":"3.37.3"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T00:00:00Z","timestamp":1597622400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.ijid.2020.08.042","type":"journal-article","created":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T06:44:22Z","timestamp":1597905862000},"page":"357-365","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Initial resistance to companion drugs should not be considered an exclusion criterion for the shorter multidrug-resistant tuberculosis treatment regimen"],"prefix":"10.1016","volume":"100","author":[{"given":"Pauline","family":"Lempens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"Decroo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kya J.M.","family":"Aung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad A.","family":"Hossain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leen","family":"Rigouts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Conor J.","family":"Meehan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armand","family":"Van Deun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bouke C.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10150","key":"10.1016\/j.ijid.2020.08.042_bib0005","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(18)31644-1","article-title":"Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis","volume":"392","author":"Ahmad","year":"2018","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ijid.2020.08.042_bib0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001300","article-title":"Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients","volume":"9","author":"Ahuja","year":"2012","journal-title":"PLoS Med"},{"issue":"10","key":"10.1016\/j.ijid.2020.08.042_bib0015","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.5588\/ijtld.14.0100","article-title":"Successful\u2019 9-month Bangladesh regimen\u2019 for multidrug-resistant tuberculosis among over 500 consecutive patients","volume":"18","author":"Aung","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"10.1016\/j.ijid.2020.08.042_bib0020","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13073-015-0164-0","article-title":"Rapid determination of anti-tuberculosis drug resistance from whole-genome sequences","volume":"7","author":"Coll","year":"2015","journal-title":"Genome Med"},{"issue":"11","key":"10.1016\/j.ijid.2020.08.042_bib0025","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1164\/rccm.201910-1960OC","article-title":"Early bactericidal activity of different isoniazid doses for drug resistant TB (INHindsight): a randomized open-label clinical trial","volume":"201","author":"Dooley","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"15","key":"10.1016\/j.ijid.2020.08.042_bib0030","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1001\/jama.1996.03540150031027","article-title":"A multi-institutional outbreak of highly drug-resistant tuberculosis: epidemiology and clinical outcomes","volume":"276","author":"Frieden","year":"1996","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.ijid.2020.08.042_bib0035","doi-asserted-by":"crossref","first-page":"e00092","DOI":"10.1128\/AAC.00092-19","article-title":"Isoniazid resistance in mycobacterium tuberculosis is a heterogeneous phenotype composed of overlapping mic distributions with different underlying resistance mechanisms","volume":"63","author":"Ghodousi","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.ijid.2020.08.042_bib0040","first-page":"139","article-title":"A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis","volume":"12","author":"Katiyar","year":"2008","journal-title":"Int J Tuberc Lung Dis"},{"issue":"12","key":"10.1016\/j.ijid.2020.08.042_bib0045","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1101\/gr.210641.116","article-title":"Salzberg SL. Centrifuge: rapid and sensitive classification of metagenomic sequences","volume":"26","author":"Kim","year":"2016","journal-title":"Genome Res"},{"key":"10.1016\/j.ijid.2020.08.042_bib0050","doi-asserted-by":"crossref","first-page":"e5895","DOI":"10.7717\/peerj.5895","article-title":"MTBseq: a comprehensive pipeline for whole genome sequence analysis of Mycobacterium tuberculosis complex isolates","volume":"6","author":"Kohl","year":"2018","journal-title":"PeerJ"},{"issue":"1","key":"10.1016\/j.ijid.2020.08.042_bib0055","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1038\/s41598-018-21378-x","article-title":"Isoniazid resistance levels of Mycobacterium tuberculosis can largely be predicted by high-confidence resistance-conferring mutations","volume":"8","author":"Lempens","year":"2018","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.ijid.2020.08.042_bib0060","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13073-019-0650-x","article-title":"Integrating informatics tools and portable sequencing technology for rapid detection of resistance to anti-tuberculous drugs","volume":"11","author":"Phelan","year":"2019","journal-title":"Genome Med"},{"key":"10.1016\/j.ijid.2020.08.042_bib0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2019.105844","article-title":"Management of multidrug-resistant tuberculosis with shorter treatment regimen in Niger: nationwide programmatic achievements","volume":"161","author":"Piubello","year":"2020","journal-title":"Respir Med"},{"issue":"2","key":"10.1016\/j.ijid.2020.08.042_bib0070","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/jac\/dkv360","article-title":"Specific gyrA gene mutations predict poor treatment outcome in MDR-TB","volume":"71","author":"Rigouts","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2020.08.042_bib0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100268","article-title":"Outcomes of a nine-month regimen for rifampicin-resistant tuberculosis up to 24 months after treatment completion in nine African countries","volume":"20","author":"Schw\u0153bel","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"3","key":"10.1016\/j.ijid.2020.08.042_bib0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0119628","article-title":"Genetic mutations associated with isoniazid resistance in Mycobacterium tuberculosis: a systematic review","volume":"10","author":"Seifert","year":"2015","journal-title":"PLoS One"},{"issue":"Suppl 3","key":"10.1016\/j.ijid.2020.08.042_bib0085","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1093\/cid\/civ610","article-title":"Collaborative effort for a centralized worldwide tuberculosis relational sequencing data platform","volume":"61","author":"Starks","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.ijid.2020.08.042_bib0090","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3390\/jcm9010055","article-title":"Short-course regimen for multidrug-resistant tuberculosis: a decade of evidence","volume":"9","author":"Tr\u00e9bucq","year":"2019","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.ijid.2020.08.042_bib0095","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5588\/ijtld.17.0498","article-title":"Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries","volume":"22","author":"Tr\u00e9bucq","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"issue":"9","key":"10.1016\/j.ijid.2020.08.042_bib0100","doi-asserted-by":"crossref","first-page":"965","DOI":"10.5588\/ijtld.19.0053","article-title":"Gatifloxacin is superior to levofloxacin and moxifloxacin in shorter treatment regimens for multidrug-resistant TB","volume":"23","author":"Van Deun","year":"2019","journal-title":"Int J Tuberc Lung Dis"},{"issue":"3","key":"10.1016\/j.ijid.2020.08.042_bib0105","doi-asserted-by":"crossref","first-page":"239","DOI":"10.5588\/ijtld.17.0660","article-title":"Principles for constructing a tuberculosis treatment regimen: the role and definition of core and companion drugs","volume":"22","author":"Van Deun","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"issue":"5","key":"10.1016\/j.ijid.2020.08.042_bib0110","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1164\/rccm.201001-0077OC","article-title":"Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis","volume":"182","author":"Van Deun","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"45","key":"10.1016\/j.ijid.2020.08.042_bib0115","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1093\/cid\/ciz039","article-title":"Improved outcomes with high-dose isoniazid in multidrug-resistant tuberculosis treatment in Haiti","volume":"69","author":"Walsh","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.ijid.2020.08.042_bib0120","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2165\/00003088-197904060-00001","article-title":"Clinical pharmacokinetics of isoniazid","volume":"4","author":"Weber","year":"1979","journal-title":"Clin Pharmacokinet"},{"author":"WHO","key":"10.1016\/j.ijid.2020.08.042_bib0125"},{"author":"WHO","key":"10.1016\/j.ijid.2020.08.042_bib0130"},{"author":"WHO","key":"10.1016\/j.ijid.2020.08.042_bib0135"},{"author":"WHO","key":"10.1016\/j.ijid.2020.08.042_bib0140"},{"issue":"6","key":"10.1016\/j.ijid.2020.08.042_bib0145","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/bdd.403","article-title":"Acetylation phenotype status in a Bangladeshi population and its comparison with that of other Asian population data","volume":"25","author":"Zaid","year":"2004","journal-title":"Biopharm Drug Dispos"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S120197122030672X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S120197122030672X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T22:55:09Z","timestamp":1738450509000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S120197122030672X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":29,"alternative-id":["S120197122030672X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2020.08.042","relation":{},"ISSN":["1201-9712"],"issn-type":[{"type":"print","value":"1201-9712"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Initial resistance to companion drugs should not be considered an exclusion criterion for the shorter multidrug-resistant tuberculosis treatment regimen","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2020.08.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}